白云山制药BYS30颗粒获临床试验批准

财中社
09 Jan

财中社1月9日电白云山(600332/00874)发布公告,旗下分公司白云山制药总厂近日获得国家药品监督管理局核准签发的《药物临床试验批准通知书》,该药物为BYS30颗粒,适应症为膝骨关节炎。药物的临床试验申请于2024年10月29日获得受理,并在满足相关药品注册要求的基础上获得批准。截至公告日,白云山制药总厂已为BYS30颗粒的研发投入约为1289万元。市场上同类产品包括仙灵骨葆胶囊、藤黄健骨片...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10